Share

ACS CAN STATEMENT: Oral Chemotherapy Committee Vote Deeply Disappointing

May 19, 2015

FOR MORE INFORMATION, CONTACT:
Amber Hillman
American Cancer Society Cancer Action Network
Phone: 508-450-8690 (cell)
E-mail: [email protected]

 

ACS CAN Statement on Oral Chemotherapy Fairness Committee Vote

The following can be attributed to Mike Rollo, New Hampshire director of government relations for the American Cancer Society Cancer Action Network (ACS CAN):

“The American Cancer Society Cancer Action Network (ACS CAN) is deeply disappointed in the House Commerce Committee's decision to retain Senate Bill 137, which would ensure cancer patients have affordable access to potentially lifesaving oral chemotherapy. Unfortunately, for many cancer patients, time is not a luxury they can count on – and the time spent studying this bill may result in lives lost.

“Despite the fact that an estimated 8,090 Granite Staters will be diagnosed with cancer this year and over 2,730 will lose their battle with the disease, we are running behind when it comes to ensuring cancer patients have access to the most effective forms of treatment without having to be concerned with outrageous co-pays. Now is the time for New Hampshire to join 39 other states and Washington DC in ensuring affordable access to oral chemotherapy.”

ACS CAN, the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society, supports evidence-based policy and legislative solutions designed to eliminate cancer as a major health problem.  ACS CAN works to encourage elected officials and candidates to make cancer a top national priority. ACS CAN gives ordinary people extraordinary power to fight cancer with the training and tools they need to make their voices heard. For more information, visit www.fightcancer.org.

###